Please login to the form below

Not currently logged in
Email:
Password:

David Noble to leave Edelman

David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure

David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure.

Noble has been heading the agency's specialist medical communications business unit for more than three years. He is to leave this month following a three-week consultation process.

Steve Spurr who leads Edleman's ethical healthcare division will take over Noble's responsibilities.

Robert Phillips, Edelman UK CEO told PR Week: "The BioScience and Rx divisions will remain separate, but will be headed by Steve. We are reorganising internally to have more fluent interaction between the teams."

The BioScience division specialises in advisory board management, clinical trial recruitment/retention, market access support, publication planning, meetings and symposia.

13th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

What does HCP engagement look like in a post-Covid world?
HCP engagement has changed as a result of the Covid-19 pandemic, with pharmaceutical companies and agencies having to rapidly adjust to a new way of communicating. Digital channels have become...
Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...